相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer
Xiang-Hong Chen et al.
BIOMARKERS IN MEDICINE (2019)
Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis
Shi-Yi Wang et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal
Shi-Yi Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma
Jing Li Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score
Parker C. Wilson et al.
BREAST JOURNAL (2018)
The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
Jun Wang et al.
FRONTIERS IN GENETICS (2018)
An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer
Jesse L. Felts et al.
BREAST JOURNAL (2017)
Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast
Scott Kizy et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma
Michaela L. Tsai et al.
CLINICAL BREAST CANCER (2016)
Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer
Soo Youn Bae et al.
BMC CANCER (2015)
Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective
Michelle Kip et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2015)
The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients
Toshinao Onoda et al.
BREAST CANCER (2015)
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics
Amy E. McCart Reed et al.
BREAST CANCER RESEARCH (2015)
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK
S. Holt et al.
BRITISH JOURNAL OF CANCER (2013)
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer
J. A. Davidson et al.
EUROPEAN JOURNAL OF CANCER (2013)
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis
S. Ward et al.
HEALTH TECHNOLOGY ASSESSMENT (2013)
Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Impact of Progesterone Receptor Semiquantitative Immunohistochemical Result on Oncotype DX Recurrence Score
Beth Z. Clark et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative
Jigisha P. Thakkar et al.
ONCOLOGIST (2011)
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment
J. M. Bueno-de-Mesquita et al.
ANNALS OF ONCOLOGY (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Loss of 16q in High Grade Breast Cancer is Associated with Estrogen Receptor Status: Evidence for Progression in Tumors with a Luminal Phenotype?
Rachael Natrajan et al.
GENES CHROMOSOMES & CANCER (2009)
Predicting features of breast cancer with gene expression patterns
Xuesong Lu et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Laurel A. Habel et al.
BREAST CANCER RESEARCH (2006)
Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes
M Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)